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Background: The World Health Organization (WHO) selected antimicrobial resistance (AMR) as the theme for World
Health Day 2011. The slogan was “Combat Drug Resistance – No action today, no cure tomorrow” A six-point policy
package was launched as a core product for World Health Day. It aimed to stimulate extensive and coherent action
to overcome the many challenges presented by antimicrobial resistance.
Methods: As a preparation for World Health Day, interviews were conducted with a series of key informants, mainly
senior government staff, to assess their awareness of the topic and the interventions proposed in the policy
package. Since the key informant interview methodology was used with a small number of interviewees, it may be
difficult to demonstrate the validity of the findings.
Results: Key informants from twelve out of fifteen countries responded, which included Fiji (n = 5), Kiribati (n = 1),
Lao PDR (n = 2), Malaysia (n = 6), Micronesia (n = 3), Mongolia (n = 5), the Philippines (n = 5), Vietnam (n = 6),
Vanuatu (n = 1), Solomon Islands (n = 3), Cambodia (n = 5) and Brunei (n = 1). There was a total of forty-three
respondents (n = 43). AMR was widely recognized as a problem. Lack of a coherent, comprehensive and national
plan or strategy was noted. Surveillance was often seen as weak and fragmented even where presented. Laboratory
capacity was felt to be insufficient across all countries interviewed. The majority of respondents stressed the need
for national and local plans to combat AMR including reliable estimates of the financial cost of combating and
managing AMR, the need for legislation to control inappropriate use of antimicrobials in food animals and more
serious efforts to promote Standard Treatment Guidelines (STGs) and Rational Prescription. Also, importance was
highlighted of the need to include infection prevention and control (IPC) as a part of accreditation and registration
of health institutions and programs to promote IPC to the general population.
Conclusion: A coalition of interested parties at the local, national and international levels need to generate and
sustain the political will to organize a more comprehensive, sustainable, and coherent approach to AMR.
Keywords: Antimicrobial resistance (AMR), Key informant interview (KII), Western pacific region, World health day,
World health organization (WHO)* Correspondence: leeyu@wpro.who.int
1Health Services Development Unit, World Health Organization, Western
Pacific Regional Office, P.O. Box 2932, United Nations Avenue, Manila 1000,
Philippines
2Institute of Health Services Research, Yonsei University, Seoul, South Korea
© 2013 Lee and Wakabayashi; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Lee and Wakabayashi Globalization and Health 2013, 9:34 Page 2 of 7
http://www.globalizationandhealth.com/content/9/1/34Background
Among the most important medicines ever discovered,
antimicrobial agents have saved millions of lives and im-
proved the outcomes for countless patients since these
drugs were introduced in the early 1930s [1]. However,
the emergence and spread of resistance in multiple mi-
croorganisms have rendered the management of many
infectious diseases more difficult [2].
Antimicrobial resistance (AMR) is defined as the resis-
tance of a microorganism to an antimicrobial medicine to
which it was previously sensitive [3,4]. Resistant organisms
including bacteria, viruses and some parasites are able to
withstand the attack by antimicrobial medicines, such as
antibiotics, antivirals, and anti-malarials, so that standard
treatments become ineffective and infections persist and
may spread to others [3]. The development of resistance
to antimicrobials may be inevitable due to natural selec-
tion and evolutionary pressure [5-8]. However, there is
little doubt that the overuse and misuse of antimicro-
bials have hastened the development of AMR [3,9,10].
The world has recognized for many years that antimicro-
bial resistance is a major problem and that comprehensive
and coordinated action is desirable [11]. In 2001, the World
Health Organization (WHO) published theWHO GLOBAL
STRATEGY FOR CONTAINMENT OF ANTIMICROBIAL
RESISTANCE along with a series of recommendations
aimed at enabling countries to define and implement na-
tional policies in response to antimicrobial resistance [4].
In 2002, the Regional Committee for the Western
Pacific passed a resolution on antimicrobial resistance that
recognized the WHO Global Strategy for Containment of
Antimicrobial Resistance [12]. The resolution urged the
Member States to develop and implement multisectoral
strategies to contain antimicrobial resistance, make anti-
microbials available only on prescription, and promote
and ensure the rational use of drugs [11,13].
The World Health Assembly resolutions related to
AMR in 1998, 2005 and 2009 and from various WHO Re-
gional Committee resolutions have been passed, but the
consensus is that national and global responses have been
inadequate [12]. Strategies for containment, with a few ex-
ceptions, have not been widely or effectively implemented.
While the actions needed are clear, a commitment to be
accountable and implement these strategies has been lack-
ing. The World Health Day, held annually on April 7, is
the flagship advocacy event of the, of which theme in 2011
was antimicrobial resistance [14]. The intention for this
theme was to partially alleviate the lack of sufficient atten-
tion to AMR. A six-point policy package launched on the
World Health Day 2011 was aimed at engaging all of
WHO’s Member States and the global health community
to foster action for change [11].
The six-point policy package was proposed as a core
product for World Health Day. It was developed fromthe WHO Global Strategy for Containment of AMR
[15]. The package was distilled from the existing stra-
tegy, but aimed to be more direct, more coherent and
easier to understand. The package was built around
identified problems and proposes actions to address
them. It also recognized that the action stimulated by
previous WHO resolutions and strategies had been inad-
equate and aimed to stimulate extensive and coherent
action to overcome its present challenges [3].
The six items in the six-point policy package were: (1)
to commit to a comprehensive, financed national plan
with accountability and civil society engagement, (2) to
strengthen surveillance and laboratory capacity, (3) to
ensure medicines of good quality and of regular supply,
(4) to regulate and promote the rational use of medi-
cines including those in animal husbandry and ensure
proper patient care, (5) to enhance infection prevention
and control, and (6) to foster innovations and research
and development of new tools [12].
The Western Pacific Regional Office (WPRO) of
WHO, as a part of its preparation for World Health
Day, commissioned key informant interviews with key
policy makers in the area of AMR in individual member
states. The purpose of the interview was for the key in-
formants to assess the relevance and suitability of the
proposed policy package. It also provided an opportunity
to see if senior decision makers had knowledge about
whether or not the proposed key aspects of the AMR
policy package were in place and to sensitize them on
the need of the AMR policy package to guide actions
against AMR at the country level.
Methods
The Health Services Development unit developed an in-
strument for use in conducting key informant inter-
views. The questionnaire for structure interview was
commented upon and refined by members of the AMR
Working Group of the WPRO.
Key informant interviews (KII) involve interviewing a se-
lect group of individuals who are likely to provide needed
information, ideas, and insights on a particular subject.
Because information comes directly from knowledgeable
people, KII often provide data and insight that cannot be
obtained by other methods. But, because KII provide only
a very limited basis for quantification, they are rarely ap-
propriate when quantitative data are needed. Moreover,
having a small sample pool may prove difficult to demon-
strate the validity of the findings [16].
The instrument followed the format of the six-point
policy package and consisted of a quantitative and a
qualitative part. Each of the six-points had 5–6 closed-
ended questions which required a “Yes”, “No”, or “Do
Not Know (DNK)” answer. These were then linked to an
open-ended question on the same topic that was used to
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naire was an applied mixture of both self-reporting and
face-to-face interviews conducted by the Health Services
Development unit of WPRO, WHO.
The interviewees were identified by the WHO country
offices in their respective regions in cooperation with
the focal point in the Ministry of Health (MoH). The in-
terviewees were typically a senior researcher from a local
research institute or an official from the MoH. The task
involved identifying the officials from the MoH in diffe-
rent departments. Given the time constraints in accessing
senior policy makers, the focal point persons from the
MoH and WHO were asked to help make arrangements
for the interviews. Due to the time limits and budget con-
straints, it was not possible to carry out interviews with
the private sector and professional associations.
The questionnaire could be completed by the key in-
formant independently or through a face-to-face inter-
view. An Interview took about 30 minutes. Key
informants felt comfortable with the “Yes”, “No”, and
“DNK” questions, but for the more detailed comment
questions, some felt unease as it required more time and a
more thorough discussion. The interviews were conducted
only in the Member States of the Western Pacific Region
where the WHO had an office, which meant that the ma-
jority of the responses gathered were from low and
middle-income countries. The plan was to have three to
five interviews per country, with five from the larger coun-
tries and three from the smaller.
Results and discussion
Interviewees from twelve out of fifteen countries
responded, which included Fiji (n = 5), Kiribati (n = 1),
Lao PDR (n = 2), Malaysia (n = 6), Micronesia (n = 3),
Mongolia (n = 5), the Philippines (n = 5), Vietnam (n = 6),
Vanuatu (n = 1), Solomon Islands (n = 3), Cambodia (n = 5),
and Brunei (n = 1). The total number of respondents was
forty-three (n = 43). Respondents identified themselves
from a wide variety of professions including pharmacists,
medical doctors, physicians, pathologists, medical micro-
biologists, bacteriologists, public health specialists, health
administrators, family medical consultants, laboratory sci-
entists and epidemiologists.
Because small samples were chosen and random sam-
pling methods were not used, it would not be safe to make
generalizations about the results. However, the KII pro-
vides valuable information for programs, particularly when
following the general process and steps. In this study, it
first identified stakeholders and what information is
needed and from whom. Second, developing an interview
protocol, which is the rule that guides the administration
and implementation of the interview, was done. Third, in-
terviews with stakeholders were set up after explaining the
purpose of the interview, why he/she has been chosen, theexpected duration of the interview, while an informed
consent was asked of the interviewee.
Key informants results
The answers to the closed-end questions are presented
in detail in Table 1. It is emphasized that the sampling
method and sample size did not lead to numbers that
are considered statistically significant. However, the data
do provide a general view of the opinions of decision
makers about the questions which is of value.
The questions focused on the national planning pro-
cesses indicate that most informants were not aware of a
comprehensive national plan and that there was not an
estimate available as to the costs of combating AMR.
Also, only 40 % of the respondents answered they were
aware of which individual or organizational body was re-
sponsible for AMR in their country.
The second set of questions revealed a lack of confi-
dence in the existence of comprehensive surveillance
systems for AMR, although there was a better response
in regards to some disease specific systems being in
place. Only 50 % thought they were aware of who is re-
sponsible for AMR surveillance while only 28 % felt that
laboratory capacity was adequate for AMR surveillance.
A majority of the respondents answered positively to
the third set of questions aimed at assessing the ability
to ensure medicines of good quality and regular supply.
The fourth set of questions dealt with the rational use of
medicines to which the informants were less positive. It
is of particular interest that only 7 % of respondents felt
there was sufficient legislation to control the use of anti-
biotics in animal feed.
The responses to fifth set of questions dealt with infec-
tion prevention and control (IPC) seemed to indicate that
there was considerable activity in institutions although
IPC was not a part of the health institution accreditation.
Informants also felt there was not an adequate program to
promote IPC in the general population. The final set of
questions dealt with fostering innovation and research.
About forty per cent of respondents felt that operational
research was being conducted relevant to AMR and that a
process existed for the assessment of new antimicrobials
and diagnostics. Not surprising for low and middle income
countries, the informants had a relatively low-awareness
of basic research in respect to AMR.
Summary of open questions
The first item in the six-point policy package concerns
the commitment to a comprehensive, financed national
plan with accountability and civil society engagement.
The key informants agreed that a comprehensive na-
tional plan for AMR is needed and there is a need for
developing plans to strengthen existing related activities
in order to combat AMR. One respondent was not sure
Table 1 Quantitative data of responses from key informant consultation on AMR
Question Yes No DNK
1. Commit to a comprehensive, financed national plan with accountability and civil society engagement
1a. Does your country have a comprehensive national plan to combat or manage the problem of antimicrobial resistance? 4 28 9
(9.8) (68.3) (22.0)
1b. Are local or institutional plans in place for combating or managing antimicrobial resistance even if no national plan? 25 10 5
(62.5) (25.0) (12.5)




1d. Is it clear to you who (person or body) is responsible for combating or managing antimicrobial resistance in your country? 17 16 9
(40.5) (38.1) (21.4)
1e. Are partners other than the government involved in combating or managing antimicrobial resistance in your country? 19 15 6
(47.5) (37.5) (11.2)
2. Strengthen surveillance and laboratory capacity
2a. Is there a comprehensive AMR surveillance system in your country? 12 23 7
(28.6) (54.8) (16.7)
2b. Are there surveillance systems for AMR in specific organisms such as HIV, malaria, TB, or influenza in your country? 27 5 10
(64.3) (11.9) (23.5)
2c. Is it clear to you who is responsible for AMR surveillance in your country? 21 13 8
(50.0) (31.0) (19.0)
2d. Is there sufficient laboratory capacity in your country to monitory AMR? 13 23 9
(28.9) (51.1) (23.8)
2e. Do you know who is responsible for the laboratory monitoring of AMR? 20 8 12
(50.0) (20.0) (30.0)
2 f. Is there a system of monitoring or surveillance for drug consumption in your country? 17 8 12
(45.9) (20.0) (19.4)
3. Ensure medicines of good quality and regular supply
3a. Does drug quality in your country meet international standards? 27 7 8
(64.3) (16.7) (19.0)
3b. Is there a mechanism to halt or control the sale of counterfeit and substandard medicines? 30 7 5
(71.4) (16.7) (6.5)
3c. Is there a reliable supply or essential medicines to treat infections? 33 3 6
(78.6) (7.1) (14.3)
3d. Is the essential medicine list harmonized or consistent with standard treatment guidelines? 33 2 7
(76.6) (4.6) (16.7)
3e. Is there a method for ensuring that expired or improperly stored drugs are not used? 29 4 9
(69.0) (9.5) (21.4)
4. Regulate and promote rational use of medicines, including in animal husbandry, and ensure proper patient care
4a. Are standard treatment guidelines and continuing education used as part of health provider registration accreditation? 20 14 9
(46.5) (32.6) (20.9)
4b. Are antimicrobials available only by prescription from a trained health worker? 23 18 2
(53.5) (41.9) (4.7)




4d. Is there legislation to control the inappropriate use of antimicrobials in food animals? 3 20 20
(7.0) (46.5) (46.5)
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Table 1 Quantitative data of responses from key informant consultation on AMR (Continued)
4e. Is there any public education on appropriate use of antimicrobials? 15 24 4
(34.9) (55.8) (9.3)
5. Enhance infection prevention and control
5a. Do standards for infection prevention and control (IPC) for health care institutions exist? 32 5 4
(78.0) (12.2) (9.8)
5b. Is adequate IPC part of health institution accreditation or registration in your country? 13 22 6
(31.7) (53.7) (14.6)
5c. Is there a continuing education programme to promote IPC among health workers? 25 9 7
(61.0) (22.0) (17.1)
5d. Is there a programme to promote IPC among the general population? 12 23 6
(29.3) (56.1) (14.6)
5e. Do you know who is responsible for IPC in your country? 31 6 4
(75.6) (14.6) (9.8)
6. Foster innovations and research and development of new tools
6a. Is operational research being done to improve the use of existing antimicrobials? 16 14 12
(38.1) (33.3) (28.6)
6b. Is research being done to improve the use of existing diagnostic methods for AMR? 13 17 12
(31.0) (40.5) (28.6)
6c. Is basic research being done to develop new antimicrobials in your country? 4 27 11
(9.5) (64.3) (26.2)
6d. Is basic research being done to develop new diagnostics in your country? 9 19 14
(21.4) (45.2) (33.3)
6e. Is there a process to assess whether new antimicrobials and diagnostic should be introduced? 17 14 11
(40.5) (33.3) (26.2)
Number (%).
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the existing fragmentation. The majority said that the local
AMR plans should be developed, although one informant
felt that given the national guidelines are present, there is
no need for local plans. Another informant said that a
local plan should be demanded by the national plan. The
majority responded that costing is definitely needed and
useful. The majority of the sample felt that the MoH or its
equivalent within the government should be responsible
for AMR, although there is recognition that there are
many other stakeholders concerned.
The second item is about strengthening surveillance
and laboratory capacity. Most respondents said a com-
prehensive AMR surveillance system needs to be
established and there is a need to develop an institution
or department for the improvement of technical capacity
for AMR surveillance. Some specific diseases, such as
TB, HIV, Influenza, MRSA, VRE, and gonococcus, are
established as reportable diseases and have ongoing sur-
veillance. Some of the respondents mentioned surveil-
lance should be expanded to other diseases and be
better linked with each other. Many different organiza-
tions and departments play a role in surveillance, butsome countries have no specific person taking responsi-
bility. In most countries the National Laboratory coor-
dinator in the MoH is responsible for AMR laboratory
capacity. However, improving skills and equipment,
training, budget, human resources and capacity of all re-
lated resources and facilities as well as premises are
needed. Moreover some countries have no database for
regulation at the national level, but many countries pre-
pare annual reports published by the public sector.
The third item is about ensuring medicines of good
quality and regular supply. Many respondents said the
national standards on prescribing medications exist, but
related law and standards enforcement and their imple-
mentation are inadequate. Lack of laboratory capacity, il-
legal drug use and supply, and procurement systems
that fail to comply with standard procedures contribute
to AMR. While control measures by regulations and en-
forcement by the government officials exist for counter-
feit and substandard medicines, the implementation of
these control measures is imperfect. National drug com-
mittees such as the drug and therapeutic committees
and disease program managers in the MoH should regu-
larly review essential drug lists (EDLs) and standard
Lee and Wakabayashi Globalization and Health 2013, 9:34 Page 6 of 7
http://www.globalizationandhealth.com/content/9/1/34treatment guidelines (STGs), but these mechanisms are
often not functioning well at the moment. With regard
to expired drugs, the majority of the countries’ respon-
dents felt expired drugs are being destroyed appropri-
ately by legal regulations or protocols.
The fourth item concerns the regulation and promo-
tion of the rational use of medicines, including in the
area of animal husbandry, and ensuring proper patient
care. STGs related to combating AMR are not a part of
institutional accreditation or health worker registration
for the most part. Most informants agreed that policy
development is needed in these areas. Many of the coun-
tries have laws for the accessibility of antimicrobials only
by prescription, but are not enforced properly, although
many informants felt this law was necessary, enforcing
this law has been difficult. Most of the countries also do
not have legislation to control the inappropriate use of
antimicrobials in food animals. The general response
from some countries is that this control is partially met
by the Ministry of Agriculture (MoA), however key in-
formants from the health sector seemed to have little de-
tail or knowledge in this area. With regard to the
general public, key informants believed the public had
little knowledge of AMR and had very little access to
public education of AMR. They believe public education
on AMR through all appropriate mediums is needed.
The fifth item in the AMR policy package is enhancing
infection prevention and control (IPC). Most countries
have departments in charge of IPC. Some countries,
namely Malaysia and the Philippines, have made IPC a
part of their institutional accreditation system. While
most of the other countries do not have such a system,
there is a consensus for the need for its development.
Some countries have a system for continuing education
for health workers, while others do not. All informants
agreed to its need. Most countries do not have IPC pro-
grams for the general public, although educational pro-
grams on hand-washing are carried out during
outbreaks. There seems to be less incentive to continue
such programs indefinitely, which would be needed for
ongoing issues such as combating AMR. Some countries
have specific departments for IPC, while others do not.
The sixth item is on fostering innovations and re-
search as well as the development of new tools. Most of
the country informants felt the need for operational re-
search in the use of antimicrobials and diagnostics. Most
informants felt that there was not an adequate process
to assess whether new antimicrobials and diagnostics
should be introduced. The informants felt that basic re-
search to develop new diagnostics and antimicrobials is
needed, although those of many countries acknowledged
a limited capacity to do such research.
The key informants seemed to uniformly feel that AMR
is an important issue and there was a need to developinformation systems and infection control policy. AMR
was identified as a major challenge to the respective MoH
and it was acknowledged that they were not yet operating
properly to meet this challenge. The informants identified
the need to understand the roles and responsibilities of
various parties and to develop sufficient knowledge and
strong systems. Many acknowledged the need to make a
comprehensive management team and task force respon-
sible for AMR. They also expressed the need to develop a
stronger political will to confront the issues.
To the question on what should be expected from the
WHO (or other international organizations), the responses
included: 1. technical support (training, improvement of
the legal environment, human and laboratory capacity,
behavior change and advocacy); 2. facilitation of informa-
tion sharing; 3. advocacy on the international level; 4. ca-
pacity building and coordinating in planning country wide
training or education programs; and 5. developing instru-
ments, guidelines and policy.Key findings and conclusions
The key informants recognized AMR as a problem and
that the response to date has been inadequate. They felt
that there has been a lack of coherent, comprehensive na-
tional planning and strategic processes. Where there has
been a response to AMR, it has often been fragmented.
AMR surveillance is often shown to be weak, and even
where surveillance is stronger, it is often disease-specific
and fragmented. Laboratory capacity was felt to be insuffi-
cient in all countries interviewed. The majority of respon-
dents stressed the need for national and local plans to
combat AMR including reliable estimates of the financial
cost to combat and manage AMR. AMR surveillance in
the Region will be strengthened by increasing the number
of monitoring laboratories in different locations. They also
expressed a need for legislation to control the inappropri-
ate use of antimicrobials in food animals, although it was
also recognized that the political will needed to be gener-
ated for this step to occur.
More serious efforts to promote the STGs and rational
prescription were also deemed desirable. The STGs exists
in most settings but lacks a strong connection between
the STGs and accreditation or licensing. Antibiotics being
available without a prescription from a medical practi-
tioner were a problem in most of the countries surveyed.
Infection prevention and control activities exist, but many
were related to outbreaks. It calls for a movement move to
make these activities a part of the daily routine, as AMR is
a problem that will continue indefinitely. The strengthen-
ing of the capacity and capability of drug regulatory au-
thorities through direct technical support to selected
Member States and sharing information through the net-
work and will continue to be an area of priority.
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tainable. It is not a problem that can be confronted,
defeated and forgotten. It requires action from a wide va-
riety of players from multiple sectors in society. These key
informant interviews show that the response to AMR to
date is felt to have been inadequate in most countries.
However, this study also indicates that these key infor-
mants are aware of most of the related issues and that they
have a willingness to tackle them. They accept as clear and
relevant the six-point policy package being promoted by
the WHO as clear and relevant. However, there is some
skepticism as to whether the necessary political commit-
ment on the part of both national and international deci-
sion makers needs to be present to actually implement the
package. A coalition of interested parties at the local,
national and international levels need to generate and
sustain the political will to organize and sustain a more
comprehensive and coherent approach to AMR.
It is troubling that AMR has been recognized as an
important issue for decades [17,18], and that actions that
are effective in blunting its impact and slowing its spread
are known, but concerted and effective implementation
of these actions is still sub-optimal. It remains to be seen
whether this situation is changing. Time is not on our
side on this issue.Key messages
 Antimicrobial Resistance (AMR) is widely
recognized as a problem and the need for a
comprehensive national plan or strategy was noted.
 Surveillance is often seen as weak and fragmented
even where present, and laboratory capacity is felt to
be insufficient almost everywhere.
 The majority of respondents stressed the need for
national and local plans to combat AMR including
reliable estimates of the financial cost of combating
and managing AMR, the need for legislation to
control inappropriate use of antimicrobials in food
animals and more serious efforts to promote the
Standard Treatment Guidelines (STGs) and Rational
Prescription.
 Also, the importance is highlighted of the need to
include infection prevention and control (IPC) as a
part of accreditation and registration of health
institutions and programs to promote IPC to the
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